SUMMARY
The effects of atracurium (initial dose 0.5 mgkg~1; incremental doses 0.2 mg kg~1) and vecuronium (initial dose 0.1 mg kg~1; incremental doses 0.04 mg kg' 1 
) are described in patients with portal hypertension and some degree of liver dysfunction, and the findings compared with those from normal patients. With these doses there was no evidence of gross resistance to the two neuromuscular blockers in the patients with liver problems, although the duration of action of the initial dose was somewhat shorter, and the same may have been true of incremental doses. The method of elimination would suggest that atracurium may be the better drug in patients with severe liver dysfunction, but the use of small doses of vecuronium is not contraindicated in this type of patient.

PATIENTS AND METHODS
Patients
The patients studied were scheduled for injection sclerotherapy to oesophageal varices secondary to liver disease (table I) . Some patients were treated as emergencies after acute episodes of bleeding, whilst others were undergoing a course of elective sclerotherapy. Patients in whom there was a considerable risk of inhalation of gastric contents at the induction of anaesthesia (for example, on account of active bleeding) were excluded from the study because it was felt that a rapid sequence induction using suxamethonium would be appropriate in these particular patients.
Thirty patients (21 male) with oesophageal varices were studied; 22 received atracurium and 20 vecuronium. Twelve patients received both agents, the interval between the two consecutive anaesthetics ranging from 3 days to 5 months. Control patients (ASA grade I and II) were undergoing a wide variety of general surgical and gynaecological procedures; 25 received atracurium and 21 vecuronium. Further details have been given previously (Hunter, Jones and Utting, 1982a, b, 1984) .
Details of sex distribution, age and weight of all the patients are presented in table II. Biochemical details of the patients with abnormal liver function are shown in table III and their hepatic function classified (Child, 1964) (Child, 1964) 
Anaesthesia
Patients were premedicated with diazepam 10 mg by mouth 1 h before operation, but no premedication was given to patients with clinical signs of encephalopathy. Anaesthesia was induced with fentanyl up to 200 \ig, droperidol up to 10 mg and thiopentone 75-750 mg. While the equipment for monitoring neuromuscular function was being attached to the patient, anaesthesia was maintained with nitrous oxide 5 litre in oxygen 2 litre, using a mask (with or without an airway) and a Magill attachment. Increments of fentanyl and thiopentone were administered, if required.
Following baseline measurements of neuromuscular function, the initial dose of the myoneural blocker to be studied was administered via a rapidly running infusion of 5% dextrose. The initial dose of atracurium was 0.5 mg kg" 1 , and of vecuronium, 0.1 mg kg" 1 . Controlled ventilation via the anaesthetic mask was established as soon as practicable and tracheal intubation attempted 90 s after the neuromuscular blocker had been administered. No topical analgesia was applied to the larynx.
The anaesthetist performing tracheal intubation assessed conditions as follows: conditions were classified as "good" if the vocal cords were abducted and there was no reaction to the passage of the tube; "adequate" if the only reaction was a slight cough; and "poor" if there was considerable coughing or other movement as the tube was passed.
Controlled ventilation was continued using 70% nitrous oxide in oxygen: the patient was taken into the operating theatre and surgery commenced. A circle system was used without an absorber, the fresh gas flow and tidal volume being adjusted to give an arterial carbon dioxide tension of about 5.3 kPa (Snowdon et al., 1975) ; an infra-red carbon dioxide analyser (Datex normocap), calibrated with a mass spectrometer, was used to determine endtidal carbon dioxide tension.
Increments of fentanyl 25 [ig were given if the arterial pressure or heart rate increased during the procedure. Increments of the neuromuscular blocking drug were given when the initial twitch response of the train-of-four had returned to 20% of its initial value. The incremental dose of atracurium was 0.2 mg kg" 1 , and of vecuronium, 0.04 mg kg" 1 . At the end of the surgical procedure atropine 0.6 mg was administered followed by neostigmine 2.5 mg, 1 min later. If the height of the first twitch response of the train-of-four had not returned to 75% of control 4 min after the neostigmine had been given, atropine 0.6 mg was administered again, followed by neostigmine 2.5 mg after a further 1 min. Thus, in the patients who received two doses of neostigmine, the time interval between the two doses was 5 min.
When the first mechanical response to the trainof-four stimuli had returned to at least 75% of control (A7A) and spontaneous ventilation was adequate, anaesthesia was discontinued and monitoring of neuromuscular function disconnected before the patient became conscious.
Once the patient was able to obey commands, he was asked to lift his head and to cough as a clinical assessment of muscle power. The patient was returned to the recovery ward where he was observed for approximately 1 h. Oxygen 35% was administered by mask to the patients with liver problems. The patient was interviewed in the ward the next day and questioned about subjective experiences. Specific questions were asked with regard to residual muscle weakness or diplopia.
Monitoring
Cardiovascular function. Heart rate and systolic arterial pressure (by palpation) were recorded at 1-min intervals during induction until the mechanical response to train-of-four stimulation had disappeared. During the rest of the anaesthetic, heart rate and arterial pressure were recorded at least every 5 min. The electrocardiogram was monitored continuously. Blood-gas tensions. Blood-gas tensions were measured using a calibrated blood-gas analyser (Radiometer ABL2C) to supplement the data from the end-tidal sampler, and confirm that acid-base status was within physiological limits.
Neuromuscular function. The train-of-four stimulus (Grass S48) was used to assess neuromuscular function (Ali, Utting and Gray, 1971a, b; Ali and Savarese, 1976) . Supramaximal stimuli were applied to the ulnar nerve at the wrist via adhesive skin electrodes at a frequency of 2 Hz for 2 s. The duration of each stimulus was 0.2 s and the interval between each train was 10 s. The force of thumb adduction was measured using a force-displacement transducer (Grass FT 03C). For convenience, the initial twitch heights were designated A, B, C and D, and, during blockade, A', B', C and D'. The following times were recorded: the time from administration of the iiiitial dose of blocking drug until the first appearance of blockade; the time when the mechanical response completely disappeared or was maximally diminished; the time at which the response reappeared (when complete ablation had taken place), and the time until recovery of the first twitch height to 10% and 20% of the control height of the initial twitch. The effect of incremental doses and the recovery of the response after the administration of neostigmine and atropine were monitored. RESULTS
Initial dose: degree ofneuromuscular blockade
In the patients with varices, the mechanical response to train-of-four stimuli was ablated completely in all but one of the patients who received atracurium (95.5%) and in this one patient A7A was reduced to 2%, B', C and D' having disappeared. Of the 20 patients with varices given vecuronium, the mechanical response was completely ablated in 17 (85%): in one of the remaining three patients, A' was reduced to 3% and B', C and D' disappeared completely; in the other two, however, A' persisted at 13% and 17%, respectively, and B', C and D' were not ablated completely. All the 25 normal patients who received atracurium showed complete ablation of all twitch responses; for vecuronium the figure was 19 out of 21 (90%).
Initial dose: speed of onset ofneuromuscular blockade
The times to the first depression of the train-offour (table V) were longer with both drugs in patients with liver problems than in the normal patients. In addition, the times to maximal depression or disappearance of the response to the train-offour were longer with both drugs in liver patients, although this was statistically significant only in the group receiving atracurium. The time to first depression was significantly longer with vecuronium than with atracurium in the control patients.
Conditions for endotracheal intubation
Conditions on tracheal intubation 90 s after the initial dose of relaxant are shown in table VI. The conditions provided by both drugs were not as good in the patients with liver problems as in the normal patients. In the doses used, conditions provided by atracurium appeared to be somewhat better than those provided by vecuronium.
Initial dose: duration of action
Details of recovery time from the initial dose of neuromuscular blocker are given in table VII. This shows the times to reappearance of the twitch response after the initial dose of drug (in those cases in which the twitch responses completely disappeared) for both drugs and for both groups of patients. Corresponding data are given for time to 10% and 20% recovery of the initial twitch height.
In patients with liver problems, both the time to 10% recovery and the time to the first increment (20%) appeared to be slightly shorter than in the control group given the same drug, although statisti- 27.3f • (6.9) n=ll cal significance was achieved only for the time to 20% recovery with both drugs.
Incremental doses
Few incremental doses were given and no firm conclusions can be made. Nevertheless, the mean time to each comparable increment was shorter in those with liver problems than in the normal patients (table VIII) .
Reversal of neuromuscular blockade
The number of patients receiving two doses of neostigmine 2.5 mg was similar for both agents: for atracurium 56% for normal patients and 75% for those with varices, for vecuronium 58% and 68%, respectively. (The results depend on the ratio A7A present before the first dose of neostigmine was given. Among the normal group no mechanical response at all was evident in 5% receiving atracurium and 14% receiving vecuronium; in those with liver problems the percentages were rather higher-32% for atracurium and 35% for vecuronium.)
Figures 1 and 2 indicate graphically that the rate of return of the mechanical response in those patients with varices who were given two doses of neostigmine was similar whichever of the two neuromuscular blockers was considered, and this applied to both the ratios A7A and D7A.
Clinically acceptable antagonism of residual neuromuscular blockade was obtained in all patients. No patient complained of either residual muscle weakness or diplopia in the period after operation. 
Patients with more severe liver dysfunction
The results from the patients classified as Child's group C were analysed separately as representing the most severe degree of liver failure. Only six are available, three of whom received atracurium and three vecuronium. The values of all measured variables fell within the ranges obtained in the patients with less severe liver damage.
DISCUSSION
These two non-depolarizing neuromuscular blocking drugs appeared to be slower in onset of action in the patients with liver dysfunction than they were in the normal group. This finding is probably of no clinical importance since, in normal patients at least, suxamethonium is considerably faster than both and it seems likely that this will remain the relaxant of choice when a very rapid tracheal intubation is required as it would be, for example, in the presence of bleeding oesophageal varices.
A slower half-life of distribution in the patients with liver dysfunction might be the explanation of this slower speed of onset. The half-lives of distribution of pancuronium and fazadinium have been found to be considerably longer in cirrhotic than in normal patients (Duvaldestin et al., 1978; Duvaldestin et al., 1980) , although it should be added that, in patients with cholestasis, no such prolongation was found with pancuronium or gallamine (Westra etal.,1981) .
There was no evidence of gross resistance to either atracurium or vecuronium in the patients with liver disease. With atracurium there was some persistence of the first response of the train-of-four in one of patient with liver dysfunction, but the degree of persistence was small. Some persistence of the twitch is known to occur in normal patients with a dose of atracurium only a little less than that used (i.e. 0.4 mg kg" 1 ) (Foldes et al., 1983) . With vecuronium, however, two patients with varices did show marked persistence of response to the train-offour after the initial dose and this might be construed as some evidence of resistance. An interesting finding of this investigation was that the initial doses of both atracurium and vecuronium (and possibly the increments as well) lasted for a slightly shorter time in the patients with liver problems than they did in the normal controls (although the times taken for the initial twitch to recover from 10% to 20% of control height was similar with both drugs, and in both groups).
The liver does not seem to be involved to any great extent in the elimination of atracurium, which is mainly by the Hofmann reaction (Stenlake et al., 1983) , and Ward and Neill (1983) found that the pharmacokinetics of atracurium did not differ much from normal in patients with both hepatic and renal failure. As far as vecuronium is concerned, this finding of a shorter duration of action in patients with liver problems appears to conflict directly with the results obtained by Duvaldestin and colleagues (1982) . Using a bolus dose of vecuronium 0.2 mg kg" 1 , these workers found that the time to 75% recovery of the single twitch height was nearly twice as long in cirrhotic as in normal patients (137 min compared with 75 min), and that the time between 25% and 75% recovery was tripled (68 min compared with 21 min). Pharmacokinetic data presented by these workers showed that, in the cirrhotic patients, the plasma clearance of vecuronium was only half that of normal controls; and it might be added that their pharmacokinetic data for controls agreed well with those of Cronnelly and co-workers (1983) .
Preliminary work by the present investigators has confirmed that marked prolongation of action of vecuronium can indeed occur when large doses are given to patients with severe liver dysfunction. For example, in one such patient with obstructive disease given 0.2 mg kg" 1 , recovery of the initial twitch height to 25% of control took 3 h, three times as long as in a group of normal controls.
There seems good evidence to suppose that the liver plays some part in the elimination of vecuronium, even though some spontaneous de-acetylation also occurs (Savage, Sleigh and Carlyle, 1980) . It has been shown that exclusion of the hepatic circulation both intensifies the degree of blockade and increases its duration (Durant, Houwertjes and Agoston, 1979) , and in rats biliary excretion accounts for about half of the administered dose of the blocking drug, urinary excretion being less important (Upton et al., 1982) . It should be remembered that breakdown products of vecuronium may themselves have some degree of neuromuscular blocking activity (Marshall et al., 1982) . In the human (although not, apparently, in the rat) the liver is involved in the removal of pancuronium, which is a close cogener of vecuronium (Agoston et al., 1973; Somogyi, Shanks and Triggs, 1977; Duvaldestin et al., 1978; Ward, Judge and Corall, 1982) . In cirrhotic patients there is a marked slowing of the elimination of pancuronium (Duvaldestin et al., 1978) and fazadinium (Duvaldestin etal., 1980) . However, because a drug is, to some extent, eliminated by the liver does not mean that the termination of its action is, in all circumstances and with all doses, the result of hepatic excretion or metabolism. Matteo, Spector and Horowitz (1974) have emphasized that recovery from non-depolarizing neuromuscular blockade may depend on diffusion onto non-specific receptors (in cartilage, for example). It is possible that this sort of mechanism may be responsible for the termination of activity of the relatively small dose of vecuronium used in the current study, but when a dose twice as great is used, as by Duvaldestin and colleagues (1982) , hepatic elimination becomes of importance.
An increased volume of distribution of both atracurium and vecuronium in the patients with liver problems might explain why the duration of action of both was somewhat shorter in these patients than in normal patients. Though Duvaldestin and colleagues (1982) failed to show this in the five cirrhotic patients to whom they administered vecuronium, an increase in the volume of distribution of pancuronium (Duvaldestin et al., 1978) , fazadinium (Duvaldestin et al., 1980) and gallamine (Ramzan, Shanks and Triggs, 1981) has been found in cirrhotic patients. However, in some patients no such increase has been found (Somogyi, Shanks and Triggs, 1977; Duvaldestin etal., 1980; Westra etal., 1981) .
A possible explanation of an increase in the volume of distribution is a decrease in binding of drugs to plasma protein, and Klotz (1976) has pointed out that diminished binding is not uncommon in liver disease; such an increase in the volume of distribution of drugs which are highly bound to plasma protein and extensively metabolized will diminish the effect on impaired elimination which is seen in liver disease. In the current study no correlation was found between plasma protein fractions and duration of action of the drugs, but this is far from conclusive. In the anaesthetic literature the suggestion has been made that it is an increased binding to plasma protein in liver disease which might be responsible for the apparent resistance to nondepolarizing agents in such patients (Aladjemoff, Dikstein and Shafrir, 1958; Baraka and Gabali, 1968) . Ghoneim and co-workers (1973) investigated the plasma protein binding of tubocurarine in patients with hepatic disease and found it to be normal. Later, Duvaldestin' and Henzel (1982) , using both equilibrium dialysis and ultracentrifugation, could find no difference in the degree of binding in normal and cirrhotic patients in respect of tubocurarine, fazadinium, pancuronium and vecuronium.
The method of elimination of atracurium gives an a priori reason for considering it to be a better agent than vecuronium in patients with hepatic dysfunction, since the latter drug is eliminated, in part at least, by the liver. However, this investigation suggests that, in patients who have liver problems but who are not in the terminal stages of hepatic failure, the use of vecuronium 0.1 mg kg~l is acceptable. As most patients presented for surgery have only mild or moderate dysfunction, the drug may be of use in those who are in this category but, in the present state of knowledge, caution is required if larger doses are used and careful monitoring would seem to be a wise precaution.
